Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983552 | 0.97 | POLB (0.32) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16983264 | 0.97 | POLB (0.32) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16979154 | 0.86 | HPGD (0.34) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL9406600 | 0.84 | CYP2C9 (0.40) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL9406597 | 0.84 | CYP2C9 (0.40) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16983355 | 0.83 | NPC1 (0.34) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16979242 | 0.83 | POLB (0.33) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16979211 | 0.83 | POLB (0.33) | HPGDCYP2C9NPC1MEN1RAB9A | |
| SCHEMBL16983558 | 0.83 | SLC6A9 (0.34) | HPGDCYP2C9GAA | |
| SCHEMBL16983260 | 0.83 | SLC6A9 (0.34) | HPGDCYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783481-B2 | Carbonyl derivative, liquid crystal composition containing compound thereof and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | RCC2, RCC1, ROCK2 | HPGD 4387/4885CYP2C9 1928/4885NPC1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.